Lumida
/TVTX
⌘K
Travere Therapeutics Inc

Travere Therapeutics Inc

TVTX
$66.17USD-1.98%-1.34 today

MARKET CAP

6.2B

P/E (TTM)

FWD P/E

42.8x

DAY RANGE

$66 – $69

52W RANGE

$22
$69

AI Summary

Stalk
Buy NowMedium

The stock is powering higher in a clear Stage 2 advancing structure with a dominant Lockout Rally driving forced participation. Despite extreme overbought readings across RSI, Options Score, and stretched NTM P/E, momentum remains strong with EMAs reclaimed and steeply rising. The Lockout Rally override justifies immediate participation, using pullbacks to the 9- or 20-day EMA as reference for structural support. Caution around potential shallow pullbacks is warranted, but the near-term continuation edge favors a buy now posture.

  • Phase 3 DUPLEX: Filspari delivers proteinuria reductions sustained over five years
  • Analysts lift price targets, reflecting robust future revenue outlook
  • Negative earnings yield and low book-to-price suggest overvaluation
Full analysis →
Sales, Adj.
Gross Profit, Adj.
EBITDA, Adj.
EBIT
Net Income